15 July, 15.00-16.00 CET

This year more than half a million Europeans will be diagnosed with lung cancer. While many countries have improved the management of lung cancer through better prevention, detection, diagnosis and treatment, the disease continues to claim 1 in 5 cancer deaths across Europe, posing significant challenges to patients and healthcare systems. To identify further opportunities for improvement, The Economist Intelligence Unit made a comparative analysis of lung cancer policies across 27 countries. Over the course of 18 months almost 200 experts provided their insights and advice. During this webinar we will discuss the main findings of this new, landmark study, and discuss in particular the role that governments and policy makers can play in addressing the high burden that lung cancer presents.

8th July, 2020, 08:30 – 09:00 CET

H&N patients haven´t seen innovation in the disease area for the past 10 years. Those patients face stigma and lack of clear pathways to get early treatment. Are we all doing enough to accelerate the process? How do we make others SEE them?

17th June 2020, 11.00-12.00 CET

While Europe is working on creating a Cancer Plan, many Member States have national cancer plans and other ambitious initiatives. For example, Germany that is one year into its Decade Against Cancer. German institutions for research and healthcare, the private sector, political institutions and civil society are joining forces for cancer research, cancer prevention and improved therapy of cancer patients. Germany aims to cure or control cancer long-term in 75% of patients by 2030.
What can Europe learn from Germany, and what are the key success factors for a government driven multi-stakeholder action to improve cancer care?

10th June, 2020, 08:30 – 09:00 CET

Lung cancer is responsible for 1 in 5 cancer deaths in Europe. Last year, around half a million Europeans were diagnosed with lung cancer and 400,000 people died of the disease. The survival rates are quite low, but thanks to improvements in diagnosis, surgery, radiotherapy and medicines, they are getting better. The question is, should we screen more aggressively for lung cancer now, or not?.

20th December 2019, 9am CET

In France, it takes 530 days between market authorisation and patients having access to a new medicine. It’s 374 days in Spain, 111 in the UK, and 106 in Germany. In this webinar we discuss the current access challenges to access to new, innovative oncology treatments in Europe, as well as reforming processes to make reimbursement pathways clearer and more efficient. The objective is to foster timely and appropriate access for those patients with unmet medical needs, and increased clarity and certainty around regulatory access decisions.

Duane Schulthess discusses the Impact of the IPI on Patients, Outcomes and Innovation
21 November 2019 2.15pm ET

Vital Transformation has conducted two studies examining the impact of the proposed international reference pricing in Medicare Part D on the world-class innovative biotechnology sector in California and the United States.

23rd of October 13.00-14.00 Eastern US

This webinar presents original research by Vital Transformation that will be peer review published in Therapeutic Innovation and Regulatory Science, showing the devastating impact on R&D, Investments, and patients that will be caused by reference pricing in the United States.

With the increasing use of new regulatory tools, like the FDA’s breakthrough therapy designation, there are increasing demands for European health technology assessors (HTAs) to make an accurate assessment of the long-term value and performance of CAR-T therapies from smaller datasets and shorter outcomes. This webinar will highlight our recent publication in the BMJ, sponsored by ZIN, which showcases a novel approach to harnessing RWE and develops a longitudinal data set that can be used for effectiveness measures, even in orphan conditions. As well, we will kickoff our new research project in Diffuse large B-cell lymphoma (DLBCL) and describe how we will leverage our methodology to measure the effectiveness of the various options for treatment, both in emerging CAR-T treatments, as well as existing chemotherapy regimes and bone-marrow transplants.